Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
- PMID: 19108994
- DOI: 10.1016/j.ijantimicag.2008.10.010
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
Abstract
In 2008, 25 years after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of AIDS. These compounds fall into six categories: nucleoside reverse transcriptase inhibitors (NRTIs: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine); nucleotide reverse transcriptase inhibitors (NtRTIs: tenofovir); non-nucleoside reverse transcriptase inhibitors (NNRTIs: nevirapine, delavirdine, efavirenz and etravirine); protease inhibitors (PIs: saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir); cell entry inhibitors [fusion inhibitors (FIs: enfuvirtide) and co-receptor inhibitors (CRIs: maraviroc)]; and integrase inhibitors (INIs: raltegravir). These compounds should be used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development.
Similar articles
-
The history of antiretrovirals: key discoveries over the past 25 years.Rev Med Virol. 2009 Sep;19(5):287-99. doi: 10.1002/rmv.624. Rev Med Virol. 2009. PMID: 19714702
-
Anti-HIV drugs.Verh K Acad Geneeskd Belg. 2007;69(2):81-104. Verh K Acad Geneeskd Belg. 2007. PMID: 17550060 Review.
-
New anti-HIV agents and targets.Med Res Rev. 2002 Nov;22(6):531-65. doi: 10.1002/med.10021. Med Res Rev. 2002. PMID: 12369088 Review.
-
A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Antiviral Res. 2008. PMID: 18571246 Review.
-
Antiretroviral drugs.Curr Opin Pharmacol. 2010 Oct;10(5):507-15. doi: 10.1016/j.coph.2010.04.011. Epub 2010 May 12. Curr Opin Pharmacol. 2010. PMID: 20471318 Review.
Cited by
-
Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels.J Biol Chem. 2013 Jul 12;288(28):20683-91. doi: 10.1074/jbc.M113.472159. Epub 2013 Jun 5. J Biol Chem. 2013. PMID: 23744077 Free PMC article.
-
Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism.PLoS One. 2012;7(5):e37724. doi: 10.1371/journal.pone.0037724. Epub 2012 May 25. PLoS One. 2012. PMID: 22662200 Free PMC article.
-
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.Viruses. 2024 Sep 18;16(9):1484. doi: 10.3390/v16091484. Viruses. 2024. PMID: 39339960 Free PMC article. Review.
-
Inducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds.Antimicrob Agents Chemother. 2010 Jan;54(1):78-87. doi: 10.1128/AAC.00775-09. Epub 2009 Oct 19. Antimicrob Agents Chemother. 2010. PMID: 19841153 Free PMC article.
-
HIV protease inhibitors and obesity.Curr Opin Endocrinol Diabetes Obes. 2010 Oct;17(5):478-85. doi: 10.1097/MED.0b013e32833dde87. Curr Opin Endocrinol Diabetes Obes. 2010. PMID: 20717021 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
